18F-FDG PET/CT-based metabolic metrics in recurrent tumors of ovarian clear cell carcinoma and their prognostic implications

Table 5 Survival analyses

Univariate analysis
Variables	P (OS)			P (PRS)
Stage at initial diagnosis (Early Vs. Late)	0.006*			0.009*
Platinum response (Sensitive Vs. Resistant)	< 0.001*			0.051
Type of second-line treatment (SCS + chemo Vs. Chemo)	0.012*			0.021*
Number of relapsed lesions (Single Vs. Multiple)	0.008*			0.019*
Peritoneal carcinomatosis (No Vs. Yes)	0.001*			< 0.001*
SUVmax (Low Vs. High)^†	0.768			0.774
MTV (Low Vs. High)^†	0.083			0.128
TLG (Low Vs. High)^†	0.079			0.112
MTV40 (Low Vs. High)^†	0.141			0.091
TLG40 (Low Vs. High)^†	0.095			0.108
MTV50 (Low Vs. High)^†	0.129			0.098
TLG50 (Low Vs. High)^†	0.095			0.108
MTV60 (Low Vs. High)^†	0.129			0.098
TLG60 (Low Vs. High)^†	0.044*			0.031*
Multivariate analysis
Variables	OS			PRS
	HR	95% CI	P value	HR	95% CI	P value
Stage at initial diagnosis	1.034	0.252–4.2	0.963	2.1	0.6–7.3	0.224
Platinum response	16.5	3.2–85.2	0.001*	/	/	/
Type of second-line treatment	1.085	0.5–24.8	0.959	0.3	0.1–5.4	0.424
Number of relapsed lesions	1.1	0.3–4.2	0.862	2.8	0.7–10.8	0.140
Peritoneal carcinomatosis	12.1	2.4–61.1	0.002*	7.7	2.2–27.3	0.002*
TLG60	4.8	1.2–18.7	0.024*	2.0	0.6–6.7	0.254

†Metabolic parameters were dichotomized using the median number as cut-off value
*P values with statistical significance were denoted by bold characters in underline
Abbreviations: OS Overall Survival, PRS Post-Relapse Survival, SCS Secondary cytoreduction surgery, Chemo Chemotherapy, SUVmax Maximum Standardized Uptake Value, MTV Metabolic Tumor Volume, TLG Total Lesion Glycolysis, HR Hazard Ratio, CI Confidence Interval

ISSN: 1471-2407